News
Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed ...
Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...
Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could ...
Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a ...
1d
Zacks Investment Research on MSNBuy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July StartWall Street ended the first day of July 2025 on a mixed note. While the S&P 500 and Nasdaq suffered a fall, the Dow Jones Industrial Average gained a little. The contrasting movement witnessed across ...
Stargazers in the U.S. will find the slender form of the crescent moon roughly 20 degrees above the western horizon right at ...
This weekend, observe the waxing crescent moon align with Mars and the bright star Regulus post-sunset, creating a stunning ...
Medtronic plc (NYSE:MDT) is one of the 11 best European stocks to invest in. On June 23, the company announced the ...
Loar Holdings Inc. (NYSE:LOAR) is one of the 13 Best Aerospace and Defense Stocks to Invest in Now. On June 13, Kristine ...
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Novartis AG with a CHF102.78 average price target.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results